Phosphodiesterase-5 Inhibitors: Potential Nephroprotective Agents

Zaher Armaly1 and Zaid Abassi2,3*

1Departmental Nephrology, EMMES Nazareth–The Nazareth Hospital, Nazareth and Galilee Medical School- Bar Ilan University, Safed, Israel
2Research Unit, Rambam Health Care Campus Haifa, Israel
3Department of Physiology, Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel

*Corresponding author: Zaid Abassi, Department of Physiology & Biophysics, Rappaport Faculty of Medicine, Technion, IIT, P.O.B 9649, Haifa 31096, Israel, Tel: 972-4-8295-267; Fax: 972-4-8295-266; E-mail: abassi@tx.technion.ac.il

Received: April 22, 2014; Accepted: May 27, 2014; Published: May 31, 2014

Copyright: © 2014 Armaly Z, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

List of Abbreviations

AKI: Acute Kidney Injury; BNP: Brain Natriuretic Peptide; cGMP: Cyclic Guanosine Monophosphate; CKD: Chronic Kidney Disease; GFR: Glomerular Filtration Rate; KIM-1: Kidney Injury Molecule 1; INOS: Inducible NO Synthase; PDE5: Phosphodiesterase 5; TGF- β: Transforming Growth Factor Beta

Introduction

Sildenafil, the oldest approved Phosphodiesterase 5 (PDE5) inhibitor, was originally developed for the treatment of angina pectoris [1,2]. However, due to common side effects of enhancing penile erection among volunteers who participated in the initial clinical trials, the focus of research was shifted toward its potential beneficial effects on erectile dysfunction. Since then, besides Sildenafil (Viagra) two other PDE5 inhibitors, namely Vardenafil (Levitra) and Tadalafil ( Cialis) have been approved for the treatment of this common sexual disorder. Subsequently, these agents were found to reduce pulmonary-artery pressure and improve exercise capacity, World Health Organization functional class, and hemodynamics in patients with symptomatic pulmonary arterial hypertension [3,4], leading to the approval of Sildenafil for this indication. These effects are largely attributed to the ability of PDE5 inhibitors to relax the arterial wall leading to decreased pulmonary arterial resistance and pressure. Because PDE5 is expressed in arterial wall smooth muscle of the lungs and penis [5], PDE5 inhibitors act selectively in these organs without causing major systemic vasodilation. Besides these two organs, PDE5 is expressed in the renal tissue as was evident by PCR, northern blot and immunohistochemical analysis [6]. Actually, three isoforms of PDE5 have been identified in humans and dogs: PDE5A1, PDE5A2, and PDE5A3. PDE5 which localized to the glomeruli, mesangial cells, cortical tubules, and inner medullary collecting duct plays a critical role in the regulation of renal hemodynamics and kidney excretory function [7]. Support for the physiological importance of PDE5 at the renal level, was recently derived from NO-stimulated cGMP-forming Guanylyl Cyclase Knockout Mice (NO-GC1 KO). The relaxation of renal vasculature as determined in isolated perfused kidneys was reduced in these mice. 2-Kidney-1-Clip-Operation (2K1C) operated Wild Type (WT) mice showed a reduction of cGMP-dependent relaxation of renal vessels, which was not found in the NO-GC1 KOs. The reduced relaxation in operated WT mice was restored by sildenafil indicating that enhanced PDE5-catalyzed cGMP degradation most likely accounts for the attenuated vascular responsiveness [8].

At the cellular level, PDE5 inhibitors protect cyclic Guanosine Monophosphate (cGMP) from degradation by cGMP-specific Phosphodiesterase Type 5 (PDE5) in the target organs. cGMP is derived from either Nitric Oxide (NO) or natriuretic peptides action on soluble or particulate guanylate cyclase, respectively [2], resulting in increased cytosolic levels of cGMP, a well-known potent vasodilator.

In the last few years, research focus has shifted to the field of cardioprotective and subsequently nephroprotective properties of PDE5 inhibitors. Concerning cardioprotection, it was elegantly summarized by Reffelmann and Kloner [2], therefore the current communication will concisely focus on recent studies that support potential nephroprotective profiles of PDE5 inhibitors in both experimental and clinical research. Yet, due to the similarity between the mechanisms underlying cardiac and renal ischemic damage, the present review recognises the great advances in the cardioprotective properties of PDE5 inhibitors, which might be extrapolated to the nephroprotective profile of these agents. Therefore, a brief referral to the cardioprotective actions of PDE5 inhibitors is brought hereby.

Pre-clinical Research

Besides their vasodilatory action, PDE5 inhibitors possess anti-apoptotic and anti-oxidant properties [9], making them a promising therapy for Ischemia-Reperfusion (I/R) injury of various organs. At the cardiac level, pre-treatment with either Sildenafil or Tadalafil reduced infarct size by 68% and 25% in rabbit and rat models of myocardial infarction, respectively [10,11]. These beneficial cardioprotective effects were attributed to the ability of Sildenafil to open mitochondrial K (ATP) channels in the myocardium [10]. In this context, opening of K (ATP) channels is regarded as an essential step in signalling ischemic preconditioning [12]. Similarly, Vardenafil restored mitochondrial membrane potential in a model of ischemia of isolated rat heart [13]. It should be emphasized that mitochondrial dysfunction is largely recognized as a key mediator of variety of diseases including cardiac, neuronal and renal acute and chronic damage [14-16]. In line with this concept, several studies have demonstrated that restoration of mitochondrial function after ischemic insults may be a key target to the recovery of inflicted organs [15,16]. Recently, Whitaker et al. [16] have demonstrated that cGMP-selective PDE inhibitors stimulate Mitochondrial Biogenesis (MB) both in vitro and in vivo. Since, ischemic cardiac and renal injuries share the same cellular mechanisms, namely oxidative stress, apoptosis, and fibrosis, PDE5 inhibitors may also possess nephroprotective effects in renal ischemic injury.

Indeed, our group has evaluated the early nephroprotective effects of Tadalafil, a PDE5 inhibitor, in an experimental model of renal I/R...
All the tested PDE5 inhibitors suppressed the activation of the kidney [26]. While these studies examined the effects of PDE5 or PDE5 inhibition regulates glomerular filtration by modulating the group. After removal of the right kidney and collection of two baseline reorganization of the glomerular slit diaphragm and cytoskeleton of cells and in renal tissue derived from experimental folic acid-induced hypertension and deterioration of renal function, reduced histologic damage, inflammation and apoptosis, delayed the onset of proteinuria, and preserved renal capillary integrity in an experimental model of Chronic Kidney Diseases (CKD) induced by 5/6 nephrectomy [31]. However, the beneficial anti-proteinuria impact of Sildenafil was lost when therapy began 4 weeks after the induction of the disease; suggesting that efficacy is reduced if pathological changes are already established. Similarly, Vardenafil ameliorated renal damage in type 1 diabetic rats via restoration of cGMP levels in podocytes [32]. The nephroprotective effects of PDE5 inhibitors in models of CKD are not solely due to blood pressure lowering action [33], since they possess a potent anti-proliferative effect, preventing mesangial cell proliferation and extracellular matrix expansion [34,35]. Similarly, PDE5 inhibition induce anti-apoptotic effects, [31,36] anti-oxidative stress [37] and anti-inflammation [38] on renal cells in CKD models [33].

Clinical Research

Acute kidney injury is a common clinical problem affecting 2–7% of hospitalized patients including 5–10% of critically ill subjects [39-41]. Despite the advances in critical care medicine, AKI still poses an important clinical challenge associated with high morbidity and mortality. This is attributed to delay in diagnosis of AKI on the one hand and largely to lack of efficient treatment on the other. In this regard, several strategies have been proposed to deal with this disease. These include antioxidants and antioxidant enzyme mimetics, erythropoietin, peroxisome-proliferator-activated receptor agonists, inhibitors of poly (ADP-ribose) polymerase, carbon monoxide-releasing molecules, statins, adenosine, and acetylcysteine [39-42]. Unfortunately, the therapeutic efficacy of these approaches is inconsistent and in most cases disappointing. Compared with the many advances in the use of PDE5 inhibitors in clinical cardiac settings, to the best of our knowledge these agents were not tested in AKI clinical situations. Specifically, PDE5 inhibition resulted in important cardioprotective effects as was evident by reduction of infarct size, cardiac hypertrophy, lung edema and improved cardiac function in experimental models of heart failure or myocardial injury [2,13,43,44]. Clinical studies have also demonstrated beneficial effects of Sildenafil and Vardenafil on endothelial function [45], where chronic therapy with these agents improves endothelial function in patients with chronic heart failure. Similarly, chronic Sildenafil therapy significantly improved heart rate recovery, an important prognostic marker, in patients with heart failure [46]. In line with these findings, Guazzi et al. [47] have demonstrated that Sildenafil improves left ventricle ejection fraction, diastolic function and clinical status, suggesting a role for PDE5 inhibition in heart failure therapy. Beneficial effects of Sildenafil have been documented in patients with severe pulmonary hypertension who underwent cardiac valve replacement surgery [48]. Unfortunately, neither this study nor other relevant clinical trials reported the impact of PDE5 inhibition on kidney function, where AKI is prevalent in patients who undergo this type of cardiac surgery. It is tempting to assume that PDE5 inhibitors will improve kidney function in various renal insults including AKI and cardio-renal syndrome as was shown in experimental studies. Concerning the latter, it was shown that Sildenafil mimics the hemodynamic effects of Brain Natriuretic Peptide (BNP) in dogs with heart failure induced by rapid pacing [49]. Additional encouraging hints came from clinical trials where treatment of type-2 diabetic patients with Sildenafil for one month reduced albuminuria [50].
Lasaponara et al. [51] have tested the safety of PDE5 inhibitors in patients with erectile dysfunction and severe renal disease or those who have received renal transplants. Both sildenafil and vardenafil were found to be efficacious and well tolerated for the treatment of erectile dysfunction in patients receiving renal dialysis or transplant. At the renal level, kidney function in graft recipients was not adversely affected by sildenafil administration. The glomerular filtration rate and filtration fraction of renal grafts were significantly increased in 10 patients who received a single 100-mg dose of sildenafil. Moreover, sodium clearance was also significantly increased in sildenafil-treated patients. Significant decreases were also observed in renal vascular resistance and mean arterial pressure. Serum creatinine increased slightly from baseline in 50 transplant recipients given sildenafil 25, 50, or 100 mg as needed for 12 weeks in an open-label study. However, no effect on creatinine level was found in a second open-label study of 65 younger transplant recipients who received sildenafil 50 or 100 mg for an unspecified time period or in a randomized, controlled, crossover trial of sildenafil 25, 50, or 100 mg for 8 weeks. No negative effects of sildenafil on Clcr occurred in 20 patients who received sildenafil 50 mg for 4 weeks [51]. Blood urea nitrogen was also not significantly changed in transplant recipients who received sildenafil 50 mg. Blood chemistry and hemoglobin were also unchanged with sildenafil treatment.

The variability in the extent of the beneficial renal and extra-renal effects of the various PDE5 inhibitors in both experimental and clinical studies may stem from their selectivity to the different PDE isoforms. In this context, tadalafil is extremely selective for PDE5, but also potently inhibits PDE11, an enzyme with unknown physiological function [52]. As PDE1 is expressed in the brain, myocardium, and vascular smooth muscle cells, non selectivity with respect to this enzyme (selectivity: tadalafil>vardenafil>sildenafil) may result in vasodilation and tachycardia. Inhibition of PDE6 (selectivity: tadalafil>vardenafil congruent with sildenafil), which is expressed only in retina and functions in visual transduction, can transiently disturb vision. PDE5 inhibitors may also indirectly inhibit PDE3 by increasing cyclic guanosine monophosphate levels, thereby elevating heart rate and vasodilation while inhibiting platelet aggregation [52]. Another important aspect is the dose at which PDE5 inhibitors were tested. In the experimental studies the applied doses were higher than the clinically effective doses, raising concerns over their inhibitory effects on other PDEs isoforms. In addition, in the clinical studies a wide range of doses were applied. This aspect once again calls for a highly selective PDE5 inhibitor, which upon dose escalation will still be free from non-selective and undesired adverse effects. Such an agent will be the ideal drug candidate for nephroprotection.

Conclusions and Perspectives

The initial application of PDE5 inhibitor for erectile dysfunction has evolved to other clinical settings including heart failure, pulmonary hypertension and kidney dysfunction. These therapeutic approaches are not surprising in light of the discovery that PDE5 is expressed in a number of tissues such as lung, heart and kidney. While the cardioprotective effects of PDE5 inhibitors are supported by both experimental and to a lesser extent clinical studies, the nephroprotective effects of these agents in AKI and CKD are still emerging with limited animal studies and only one clinical trial [50]. Thus, carefully controlled large clinical studies are needed before extrapolating the encouraging experimental findings to clinical indications. Additional issue of debate involves the mechanisms underlying the cardio- and nephroprotective effects of PDE5 inhibitors. It is widely accepted that these agents exert their beneficial renal and cardiac effects via systemic and regional hemodynamics. However, since sildenafil significantly reduced necrosis and apoptosis of cultured myocytes exposed to ischemia and of renal cells, a direct effect independent of their vascular action may contribute to the cardio- and nephroprotective effects of PDE5 inhibitors [9]. Thus, it seems that PDE5 inhibitors exert their beneficial effects via multiple mechanisms which involve both hemodynamic and molecular signalling pathways, including NO and cGMP and their downstream cascade [13]. A plausible mechanism for the improvement of cardiac and renal function by PDE5 inhibition is proposed in Figure 1. Moreover, although PDE5 inhibitors have an excellent safety record, they may provoke minor side-effects, such as dyspepsia, headache, and myalgia.

![Figure 1: Schematic description of the intracellular mechanism of action of natriuretic peptides and nitric oxide and their functions in target organs.](image)

These agents increase intracellular cGMP, which causes vasodilation, diuresis, natriuresis, and other beneficial renal and cardiac effects. PDE5 degrades cGMP, thus abolishing the beneficial effects of natriuretic peptides and other substances that act via NO generation, such as bradykinin and acetylcholine. PDE5 inhibitors, protect against cGMP degradation by PDE5, thus augmenting the beneficial actions of natriuretic peptides, bradykinin, and acetylcholine. ANP: Atrial Natriuretic Peptide; BNP: Brain Natriuretic Peptide; B2: Bradykinin Receptor Type 2; cGMP: Cyclic Guanosine Monophosphate; eNOS: Endothelial Nitric Oxide Synthase; M: Muscarinic Receptor; NO: Nitric Oxide; NRPA,B: Natriuretic Peptide Receptors A,B respectively; PDE5: Phosphodiesterase 5.

In conclusion, despite the encouraging results from animal studies, till now there is insufficient evidence to support the renoprotective effects of PDE5 inhibitors in humans. Of relevance could be patients who undergo interventional procedures associated with increased risk for AKI including radiocontrast-induced nephropathy, kidney transplants, cardiopulmonary bypass surgery and critically ill patients.
References

1. Boøll M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, et al. (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:371-373.

2. Reffelmann T, Kloner RA (2006) Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des 12:3485-3494.

3. Gallé N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, et al. (2005) Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148-2157.

4. Archer SL, Michelakis ED (2009) Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 361:1864-1871.

5. Wallis RM, Corbin JD, Francis SH, Ellis P (1999) Tissue distribution of phosphodiesterase families and the effect of Sildenafil on tissue cyclic nucleotide placket function, and the contractile response of trabeculae carnaeae and aortic rings. Am J Cardio383:3C-12C.

6. Lin CS (2004) Tissue expression, distribution, and regulation of PDE5. Int J Impot Res 16 Suppl 1:8-51.

7. Dousa TP (1999) Cyclic-3’,5’-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int 55:29-62.

8. Stegbauer J, Friedrich S, Potthoff SA, Broekmans K, Cortese-Krott MM, et al. (2013) Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension. PLoS One 8: e80674.

9. Das A, Xi L, Kukreja RC (2005) Phosphodiesterase 5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280:12944-12955.

10. Ockaili R, Salloum F, Hawkins J, Kukreja RC (2002) Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 283: H1263-1269.

11. Sesti C, Florio V, Johnson EG, Kloner RA (2007) The phosphodiesterase 5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res 19:55-61.

12. Gassanov N, Nia AM, Caglayan E, Er F (2014) Remote ischemic preconditioning for the treatment of acute renal ischemia reperfusion injury: an experimental study. Kaohsiung J Med Sci 30:158-162.

13. Vaidya VS, Ferguson MA, Bonventre JV (2008) Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 48:463-493.

14. Guzeloglu M, Yalcinkaya F, Atmaca S, Bagriyanik A, Oktar S, et al. (2011) The beneficial effects of tadalafil on renal ischemia-reperfusion injury in rats. Urolnt 86:197-203.

15. Gasanov F, Aytaç B, Yuruskhan H (2011) The effects of tadalafil on renal ischemia reperfusion injury: an experimental study. Bosn J Basic Med Sci 11:158-162.

16. Akgül T, Huri E, Yagmurdu H, Aykilidiz A, Ustün H, et al. (2011) Phosphodiesterase 5 inhibitors attenuate renal tubular apoptosis after partial unilateral ureteral obstruction: an experimental study. Kaohsiung J Med Sci 27:15-19.

17. Patel NN, Lin H, Toth T, Jones C, Ray P, et al. (2011) Phosphodiesterase-5 inhibition prevents postcardiopulmonary bypass acute kidney injury in swine. Ann Thorac Surg 92:2168-2176.

18. Truong LD, Choi YJ, Tsao CC, Ayala G, Sheikh-Hamad D, et al. (2001) Renal cell apoptosis in chronic obstructive uropathy: the roles of caspases. Kidney Int 60:924-934.

19. Ballermann BJ, Marsden PA (1991) Endothelium-derived vasoactive substances induce cytoskeletal changes in cultured rat glomerular epithelial cells. J Am Soc Nephrol 2:1311-1318.

20. Knight S, Nellen H, Humphreys M, Baylis C (2007) Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to ANP in the pregnant rat. Am J Physiol Renal Physiol 292: F655-659.

21. Raj L, Baylis C (1995) Glomerular actions of nitric oxide. Kidney Int 40:28-30.

22. Sharma R, Lovell HB, Wiegmann TB, Savin VJ (1992) Vasoactive substances induce cytoskeletal changes in cultured rat glomerular epithelial cells. J Am Soc Nephrol 2:1311-1318.

23. Rodriguez-Iturbe B, Ferrebeu A, Vanegas V, Zioyrz Y, Espinosa F, et al. (2005) Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int 68:2314-2312.

24. Fang L, Radovits T, Szabó G, Mozó ME, Rossvall L, et al. (2013) Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3’,5’ guanosine monophosphate (cGMP) level in podocytes. Nephrol Dial Transplant 28:1751-1761.

25. Brown KE, Duan N, Goddard J, Webb DJ (2014) Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. Hypertension 63:5-11.

26. Kuno Y, Iyoda M, Shibata T, Hirai Y, Akizawa T (2011) Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. Br J Pharmacol 162:1389-1400.

27. Tsuiboi Y, Shankland SJ, Grande JP, Walker HJ, Johnson RJ, et al. (1996) Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. J Clin Invest 98:262-270.

28. Lee KW, Jeong JY, Lim BJ, Chang YK, Lee SJ, et al. (2009) Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. Toxicology 257:137-143.

29. Jeong HK, Lee TW, Ihm CG, Lee SH, Moon JY, et al. (2009) Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. Br J Pharmacol 162:1389-1400.

30. Oruc O, Inki K, Aki FT, Zeybek D, Muftuoglu SF, et al. (2010) Sildenafil attenuates renal ischemia reperfusion injury by decreasing leukocyte infiltration. Acta Histochem 112:337-344.

31. Bonventre JV, Yang L (2011) Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 121:4210-4211.

32. Lameire N, Hoste E (2004) Reflections on the definition, classification, and diagnostic evaluation of acute renal failure. Curr Opin Crit Care 10:468-475.

33. Schrier RW, Wang W, Poole B, Mitra A (2004) Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 114:5-14.

34. Lameire N, Van Biesen W, Vanholder R (2005) Acute renal failure. Lancet 365:417-420.
43. Guazzi M, Samaja M (2007) The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem 14: 2181-2191.

44. Maas O, Donat U, Frenzel M, Rütz T, Kroemer HK, et al. (2008) Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG. Br J Pharmacol 154: 25-31.

45. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, et al. (2000) Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 36: 845-851.

46. Guazzi M, Arena R, Pinkstaff S, Guazzi MD (2009) Six months of Sildenafil therapy improves heart rate recovery in patients with heart failure. Int J Cardiol 136: 341-343.

47. Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 4:8-17.

48. Matamis D, Pampori S, Papathanasiou A, Papakonstantinou P, Tsagourias M, et al. (2012) Inhaled NO and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension: acute effects on postoperative gas exchange and hemodynamics. Circ Heart Fail 5: 47-53.

49. Forfia PR, Lee M, Tunin RS, Mahmud M, Champion HC, et al. (2007) Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 49: 1079-1088.

50. Grover-Páez F, Villegas Rivera G, GuillénOrtíz R (2007) Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Res Clin Pract 78: 136-140.

51. Lasaponara F, Sedigh O, Pasquale G, Bosio A, Rolle L, et al. (2013) Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation. J Sex Med 10:2798-2814.

52. Supuran CT, Mastrolorenzo A, Barbaro G, Scozzafava A (2006) Phosphodiesterase 5 inhibitors—drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr Pharm Des 12: 3459-3465.